Biogen Inc. Common Stock (BIIB) — Analysis Summary
Biogen Inc. Common Stock (BIIB) has a market cap of $28.61B with year-over-year revenue growth of +2.2%. Net margin stands at 13.1%. The stock trades at a P/E ratio of 20.9.
Key Takeaways
- Revenue changed +2.2% year-over-year
- Net margin of 13.1%
- P/E ratio of 20.9
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, BIIB posted revenue growth of +2.2% and trades at a P/E of 20.9.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.